Yangbing Li

发表

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions

Jiang Liu, Reena Philip, R. Pazdur, 2020, Clinical Cancer Research.

FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review

Jiang Liu, R. Pazdur, U. Rohr, 2021, Clinical Cancer Research.

Discovery of MD-224 as a First-in-Class, Highly Potent and Efficacious PROTAC MDM2 Degrader Capable of Achieving Complete and Durable Tumor Regression

Liu Liu, Chao-yie Yang, D. McEachern, 2019 .

In Vitro Predictive Dissolution Test Should Be Developed and Recommended as a Bioequivalence Standard for the Immediate-Release Solid Oral Dosage Forms of the Highly Variable Mycophenolate Mofetil.

G. Amidon, Duxin Sun, M. R. Feng, 2022, Molecular pharmaceutics.

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.

Liu Liu, Shaomeng Wang, D. McEachern, 2018, Journal of medicinal chemistry.

Targeting Mll1 H3K4 methyltransferase activity to guide cardiac lineage specific reprogramming of fibroblasts

Hacer Karatas, Liu Liu, Shaomeng Wang, 2016, Cell Discovery.

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

Jiang Liu, R. Pazdur, R. Pragani, 2020, Clinical Cancer Research.

Development of novel PROTAC Small-Molecule Degraders of MDM2 Protein and Peptidomimetic Inhibitors Targeting WDR5-MLL1 Protein-Protein Interaction

Yangbing Li, Yangbing Li, 2018 .

Chemical suppression of specific C-C chemokine signaling pathways enhances cardiac reprogramming

Liu Liu, Shaomeng Wang, Yangbing Li, 2019, The Journal of Biological Chemistry.

Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction.

F. Cao, Elizabeth C. Townsend, Hacer Karatas, 2017, Journal of medicinal chemistry.

Simple Structural Modifications Converting a Bona Fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.

Zhaomin Liu, Shaomeng Wang, A. Aguilar, 2019, Journal of medicinal chemistry.

Model‐Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases

Jiang Liu, Xinyuan Zhang, Hao Zhu, 2022, Journal of clinical pharmacology.

Comprehensive intensive therapy for Chinese gestational diabetes benefits both newborns and mothers.

Zilian Wang, Haipeng Xiao, Yangbing Li, 2012, Diabetes technology & therapeutics.

Enhancing Cardiac Reprogramming by Suppressing Specific C-C Chemokine Signaling Pathways

Liu Liu, Shaomeng Wang, Yangbing Li, 2019, bioRxiv.

FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations

Jiang Liu, Reena Philip, K. Goldberg, 2021, Clinical Cancer Research.

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 fusion or other rearrangement.

Jiang Liu, L. Fashoyin-Aje, Martha Donoghue, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

FDA Approval Summary: Amivantamab for the Treatment of patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.

Jiang Liu, Jielin Sun, Reena Philip, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.